Advertisement

Topics

Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson's Product

20:00 EDT 8 Oct 2018 | BioSpace

MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.

Original Article: Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson's Product

NEXT ARTICLE

More From BioPortfolio on "Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson's Product"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...